GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Abstract

CD20-antibodies are believed to mediate three different mechanisms of action (MOA): 1) direct cell death (DCD)/apoptosis, 2) antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), 3) complement-dependent cytotoxicity (CDC). The relative contribution of these MOAs to the clinical